According to scientists, the Discovery of ‘new rules of the immune system’ could improve the treatment of inflammatory diseases.

Adrian Liston and James Dooley in the lab

Prof Adrian Liston and Dr James Dooley to track the anti-inflammatory regulatory T cells as they traffic through the tissue. CREDIT Louisa Wood/Babraham Institute

Could this be a breakthrough for folks with multiple sclerosis, rheumatoid arthritis or fibromyalgia?

Scientists at the University of Cambridge have discovered that a type of white blood cell – called a regulatory T cell – exists as a single large population of cells that constantly move throughout the body, looking for and repairing damaged tissue.

This overturns the traditional thinking that regulatory T cells exist as multiple specialist populations restricted to specific parts of the body. The finding has implications for the treatment of many different diseases because almost all diseases and injuries trigger the body’s immune system.

Current anti-inflammatory drugs treat the whole body rather than just the part needing treatment. The researchers say their findings mean it could be possible to shut down the body’s immune response and repair damage in any specific body part without affecting the rest. This means that higher, more targeted doses of drugs could be used to treat disease – potentially with rapid results.

“We’ve uncovered new rules of the immune system. This ‘unified healer army’ can do everything – repair injured muscle, make your fat cells respond better to insulin, and regrow hair follicles.  To think that we could use it in such an enormous range of diseases is fantastic: it’s got the potential to be used for almost everything,” said Professor Adrian Liston in the University of Cambridge’s Department of Pathology, senior author of the paper.

To make this discovery, the researchers analysed the regulatory T cells present in 48 different tissues in the bodies of mice. This revealed that the cells are not specialised or static but move through the body to where they are needed.

“It’s difficult to think of a disease, injury or infection that doesn’t involve some kind of immune response, and our finding really changes how we could control this response,” said Liston.

He added: “Now that we know these regulatory T cells are present everywhere in the body, in principle, we can start to make immune suppression and tissue regeneration treatments that are targeted against a single organ – a vast improvement on current treatments that are like hitting the body with a sledgehammer.”

Using a drug, they have already designed, the researchers have shown – in mice – that it’s possible to attract regulatory T cells to a specific part of the body, increase their number, and activate them to turn off the immune response and promote healing in just one organ or tissue.

“By boosting the number of regulatory T cells in targeted areas of the body, we can help the body do a better job of repairing itself or managing immune responses,” said Liston.

He added: “There are so many different diseases where we’d like to shut down an immune response and start a repair response, for example, autoimmune diseases like multiple sclerosis, and even many infectious diseases.”

Most symptoms of infections such as COVID are not from the virus itself but from the body’s immune system attacking the virus. Once the virus is past its peak, regulatory T cells should switch off the body’s immune response, but in some people, the process isn’t very efficient and can result in ongoing problems. The new finding means it could be possible to use a drug to shut down the immune response in the patient’s lungs while letting the immune system in the rest of the body continue to function normally.

In another example, people who receive organ transplants must take immunosuppressant drugs for the rest of their lives to prevent organ rejection because the body mounts a severe immune response against the transplanted organ. However, this makes them highly vulnerable to infections. The new finding helps the design of new drugs to shut down the body’s immune response against only the transplanted organ but keep the rest of the body working normally, enabling the patient to lead a normal life.

Most white blood cells attack infections in the body by triggering an immune response. In contrast, regulatory T cells act like a ‘unified healer army’ whose purpose is to shut down this immune response once it has done its job – and repair the tissue damage caused by it.

Reduce Multiple Sclerosis Symptom Severity [New Information!]

The foods we eat can possibly reduce the severity of our multiple sclerosis (MS) symptoms. Even more new data shows that what we eat matters!! Eating a diet that is primarily plant-based can help us get phytonutrients that may help reduce our MS symptoms and possibly reduce progression.

Multiple Sclerosis – How I Knew I Had MS

When did you “know’ you had MS or other chronic illness? Did it take some time to get diagnosed? Did your intuition, your gut, tell you something was wrong? In this video I share a bit about my MS symptoms and diagnosis story.

Twelve Unusual Symptoms of Multiple Sclerosis

Multiple Sclerosis (MS) can affect any part of the central nervous system so people with MS can experience a lot of different symptoms. In this video I share some of the unusual symptoms of MS such as Dysphagia, Dysarthria, Dysesthesia, Dysesthetic itching, Optic Neuritis, Lhermitte’s Sign, Uhthoff’s phenomenon, Pseudobulbar Affect, and more. I hope to help people understand MS and its symptoms a bit more with this video. I also hope to encourage those with MS to make diet and lifestyle changes to support their health and well-being, seek treatment through physical therapy and work with their doctors to get medications when appropriate.

Does Betaseron Actually Work for MS Long-Term [Analysis of 15-year study]

Short-term randomized trials showed that Betaseron reduces relapses, new MRI lesions, and disability progression in Multiple Sclerosis. However, has it been effective for over 15 years? This extension study of the BENEFIT trial in clinically isolated syndrome (people with a first attack of demyelinating disease) seeks to answer that question. We review the effects on relapses, MRI lesions, disability, cognitive performance, employment, and quality of life.